Michael Ulz
Stock Analyst at Morgan Stanley
(4.77)
# 115
Out of 5,118 analysts
101
Total ratings
66.67%
Success rate
35.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Overweight | $46 → $50 | $19.60 | +155.10% | 3 | Dec 9, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $81 → $95 | $80.21 | +18.44% | 5 | Dec 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $9.49 | +163.44% | 3 | Dec 4, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $45 → $48 | $69.62 | -31.05% | 6 | Nov 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $79.98 | +17.53% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $36.46 | +179.76% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $7.34 | +186.10% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $398.82 | +19.10% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.31 | +296.20% | 12 | May 9, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.28 | +864.91% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $13.47 | +115.37% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.79 | +616.85% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $2.37 | +321.94% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.00 | +601.75% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $8.26 | +226.88% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.06 | +1,786.79% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.48 | +1,193.10% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.65 | +1,438.46% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $5.65 | -46.90% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.98 | +401.67% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $28.73 | +1,640.34% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $19.72 | +305.68% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.25 | +5.26% | 3 | Jul 12, 2017 |
Dyne Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $19.60
Upside: +155.10%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Overweight
Price Target: $81 → $95
Current: $80.21
Upside: +18.44%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $9.49
Upside: +163.44%
Arrowhead Pharmaceuticals
Nov 26, 2025
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $69.62
Upside: -31.05%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $79.98
Upside: +17.53%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $36.46
Upside: +179.76%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $7.34
Upside: +186.10%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $398.82
Upside: +19.10%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.31
Upside: +296.20%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.28
Upside: +864.91%
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $13.47
Upside: +115.37%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.79
Upside: +616.85%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $2.37
Upside: +321.94%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.00
Upside: +601.75%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.26
Upside: +226.88%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.06
Upside: +1,786.79%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.48
Upside: +1,193.10%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.65
Upside: +1,438.46%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $5.65
Upside: -46.90%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.98
Upside: +401.67%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $28.73
Upside: +1,640.34%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $19.72
Upside: +305.68%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.25
Upside: +5.26%